From the Centre for Menstrual Cycle and Ovulation Research (CeMCOR), Division of Endocrinology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada; and Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada.
Received October 27, 2011; revised and accepted December 22, 2011.
Funding/support: This study was funded by private individuals’ donations to the University of British Columbia’s Centre for Menstrual Cycle and Ovulation Research (CeMCOR). Active drug and placebo were provided initially by Schering (Canada) and subsequently by Besins Healthcare International.
Financial disclosure/conflicts of interest: None reported.
The authors had independent control of research design, study administration, analysis, and publication. Donors and providers of study drugs played no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, and approval of the manuscript.
ClinicalTrials.gov: NCT00152438.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Web site (www.menopause.org).
Address correspondence to: Christine L. Hitchcock, PhD, Centre for Menstrual Cycle and Ovulation Research (CeMCOR), Division of Endocrinology, Department of Medicine, University of British Columbia, and Vancouver Coastal Health Research Institute, 2775 Laurel St, 4th Floor, Vancouver, BC, Canada V5Z 1M9. E-mail: [email protected]
